Princeton Lecture Series
June 3, 2022
9 am – 3:30 pm
8 am registration
Munich RE Conference Center
665 College Road East,
Attend in person or virtually!
Eden’s Princeton Lecture Series Returns:
Neurobiology and Autism: Genetics, Comorbidities, and Dual Diagnosis
Don’t miss this opportunity to learn from experts in neurology whose research and clinical care provides insight into comorbidities, dual diagnoses, behaviors, and potential treatments for individuals with autism spectrum disorder.
CEUs & Professional Development Hours Available (no additional charge)
The event is free for students! Use the code “student” when you register. Students must use a .edu address when registering for free.
Download the offline registration form here.
Neurological Comorbidities Seen in Autism Spectrum Disorder
Madeline Chadehumbe, MD, Children’s Hospital of Philadelphia
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder with a large heterogeneous spectrum of symptoms and severity predominantly affecting social, cognitive, and language development. Several overlapping neurological conditions are associated with this disorder, including motor impairment, epilepsy, migraine, and sleep dysfunction. These, in turn, affect behaviors that are often the most consuming and limiting aspects of this disorder. This presentation will intend to review the epidemiology, etiology and provide some clinical approaches to ASD with some insights into the future research directions.
New Developments in Autism and the Repetitive Behavior Domain
Eric Hollander, MD, Albert Einstein College of Medicine
Individuals with autism experience intrusive obsessive thoughts and compulsive repetitive behaviors, including severe rigidity, difficulty transitioning, perseveration, self-stimulatory behaviors, and narrow restricted interests. These behaviors increase over the lifespan, interfere with adaptive functioning, and are difficult to treat. This presentation will review the types and causes of repetitive behaviors in autism, and describe new treatment modalities for these symptoms. New data on cannabinoid treatments, oxytocin and vasopressin agents, and transcranial magnetic stimulation (TMS) to treat repetitive behaviors will be presented.
Neurobiology and Genetics of Autism Spectrum Disorder, and the use of Biomarkers in Diagnosis and Development of Novel Therapeutics
Gahan Pandina, PhD, Janssen Research & Development
Neurobiological and general research has identified a number of single-gene disorders and brain pathways that are associated with Autism Spectrum Disorder (ASD). Genes have led to the identification of proteins, peptides, and pathways that may be involved in the pathogenesis of ASD, and may be potentially useful as novel treatment targets. Medication development is complicated by the heterogeneous nature of ASD, and in recent years several major consortia have begun to utilize biosensors to de-risk the complexity and further enable research. These approaches have begun to help us understand how core and associated symptoms can impact individuals across the lifespan.
Bringing it All Together: Comprehensive Care Models for Autism
Mary Jane Weiss, PhD, BCBA-D, Eden Autism Services
Autistics/individuals with autism present with a complex array of biological and behavioral needs. These complexities warrant intervention from experts in multiple disciplines; ideally, these efforts should be coordinated in an interdisciplinary approach. Increasingly, the interface between biology and behavior is being identified, and therapeutic approaches are integrating the biological and behavioral aspects of autism spectrum disorder. Neurological and psychiatric comorbidities complicate the individualized experience of autistic persons, and require a highly specific approach to assessment and treatment. Behavioral science offers some assistance to medical intervention, in the form of individualized analysis. The potential for interdisciplinary collaboration is exciting, as there are behavioral implications of both medical issues and psychiatric challenges. The future of understanding and treating autism lies in a collaborative model that examines the whole person, includes the individual in treatment decisions, and focuses on outcomes that maximize personal agency, support quality of life, and reflect humane care.